AURKA and acute myeloid leukemia: By combining in silico analysis using transcriptomics data of AML patients with in vitro testing using our new AML experimental model, we also identified the potentially efficacious combination of KPT-330 with the AURKA pharmacological inhibitor alisertib to prevent CAM-DR.